5 May 2006
INPHARMATICA ANNOUNCES ISO 9001 CERTIFICATION FOR ITS ADME BUSINESS
Award confirms the high customer satisfaction that is driving continued growth in Admensa sales
Inpharmatica Ltd., the selective drug discovery company, today announces the award of ISO 9001:2000 quality certification for its comprehensive ADME (absorption, distribution, metabolism and excretion) business, Admensa™. The internationally accepted ISO 9001 Certification recognises Inpharmatica’s commitment to an exceptional quality of service and customer care within its Admensa division.
The high level of customer care and service is bringing Inpharmatica an expanding list of international companies that have chosen to work with Inpharmatica to address their ADME needs. More than 40 customers have signed up to use Admensa, including recent additions Ark Therapeutics Group PLC, KuDOS Pharmaceuticals Limited, iQur Limited and Canbex Therapeutics Limited, a spin out from UCL’s Wolfson Institute.
Admensa offers a unique combination of ADME optimisation expertise, proprietary in silico tools, laboratory services and consulting, to enable early selection of compounds with an optimal balance of drug like properties. The combined approach provides expert assessments and decision support to improve timelines and success rates from lead discovery through to candidate selection.
A module of Admensa, Admensa Interactive™, Inpharmatica’s in silico optimisation platform for drug discovery scientists, has recently been enhanced to offer improved QSAR ADME models, P450 metabolism models and unique compound prioritisation and selection methods within an intuitive, interactive design environment.
Admensa itself is an integral component of Inpharmatica’s gene-to-candidate technology platform which integrates biology- and chemistry-based drug discovery activities. The complete platform optimises target selection based on druggability and enables rapid identification of hits and selection of high quality leads and pre-clinical candidates, which are prioritised on the basis of good drug-like characteristics and clinical indication.
Commenting on the announcement, John Lisle, CEO of Inpharmatica, said:
“This ISO 9001 certification means that Inpharmatica’s customers can be even more confident that they will receive an excellent product and excellent levels of service and customer care. We have already seen high levels of customer satisfaction and the company is enjoying the extra sales that this brings.”
For more information on gaining access to Admensa please click here
- ENDS -
Founded in 1998, Inpharmatica uses predictive informatics in genomics, medicinal chemistry and ADME to improve the speed and productivity of drug discovery. The company employs around 90 professionals at its UK locations in London and Cambridge, with business development in North America and Japan. Inpharmatica’s unique proprietary technologies and skills are utilised in major discovery laboratories worldwide including Serono, Pfizer, GSK, Novartis, Sanofi-Aventis, P&G Pharmaceuticals, and Daiichi.
Inpharmatica is unique in offering discovery technologies and services which span the full breadth of research from gene through to candidate selection: the core elements are fully integrated, enabling customers to access the full end-to-end technologies, or individual components and services as required.